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Premature Truncation of a Novel Protein, RD3, Exhibiting
Subnuclear Localization Is Associated with Retinal Degeneration
James S. Friedman, Bo Chang, Chitra Kannabiran, Christina Chakarova, Hardeep P. Singh,
Subhadra Jalali, Norman L. Hawes, Kari Branham, Mohammad Othman, Elena Filippova,
Debra A. Thompson, Andrew R. Webster, Sten Andre´asson, Samuel G. Jacobson,
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The rd3 mouse is one of the oldest identiﬁed models of early-onset retinal degeneration. Using the positional candidate
approach, we have identiﬁed a CrT substitution in a novel gene, Rd3, that encodes an evolutionarily conserved protein
of 195 amino acids. The rd3 mutation results in a predicted stop codon after residue 106. This change is observed in
four rd3 lines derived from the original collected mice but not in the nine wild-type mouse strains that were examined.
Rd3 is preferentially expressed in the retina and exhibits increasing expression through early postnatal development. In
transiently transfected COS-1 cells, the RD3-fusion protein shows subnuclear localization adjacent to promyelocytic
leukemia-gene-product bodies. The truncated mutant RD3 protein is detectable in COS-1 cells but appears to get degraded
rapidly. To explore potential association of the human RD3 gene at chromosome 1q32 with retinopathies, we performed
a mutation screen of 881 probands from North America, India, and Europe. In addition to several alterations of uncertain
signiﬁcance, we identiﬁed a homozygous alteration in the invariant G nucleotide of the RD3 exon 2 donor splice site
in two siblings with Leber congenital amaurosis. This mutation is predicted to result in premature truncation of the RD3
protein, segregates with the disease, and is not detected in 121 ethnically matched control individuals. We suggest that
the retinopathy-associated RD3 protein is part of subnuclear protein complexes involved in diverse processes, such as
transcription and splicing.
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Retinitis pigmentosa (RP [MIM #268000]) encompasses a
group of retinal degenerative diseases (RDs) that severely
compromise the quality of life of affected individuals. RP
is genetically heterogeneous, with mutations in multiple
genes; to date, 168 retinal-disease loci have been mapped,
and 117 retinal disease–associated genes have been iden-
tiﬁed (RetNet Web site).1 A majority of RP-causing genes
encode proteins involved in phototransduction, photo-
receptor morphogenesis, trafﬁcking, gene regulation, and/
or splicing.2 Mutations in some of the genes are suggested
to cause a prolonged and/or increased phototransduction,
followed by decreased Ca levels, leading to photore-
ceptor-cell death.3 Despite major advances, genetic defects
have not been determined for a signiﬁcant proportion of
subjects with RP (RetNet Web site).4–6
One approach for identiﬁcation of additional human
retinopathy genes is to elucidate the molecular basis of
retinal degeneration in animal models. At least 35 strains
of mice exhibit retinal degenerative disease.7,8 Some exam-
ples of retinal degeneration (rd) mice include rd1 (Pde6b),
Rds (peripherin), rd7 (Nr2e3), and rd16 (Cep290/NPHP6),
and their known and putative biological functions closely
correspond to genes involved in human retinal disease.9–13
Mutations in their human orthologs are associated with
retinopathies.14–18
The retinal degeneration 3 (rd3) mice were originally
collected in Switzerland in 1969, were sent to the Jackson
Laboratory, were bred as different lines to establish their
Robertsonian translocation, and were later identiﬁed as
having retinal degeneration.19 Different strains of rd3have
variable phenotypes, with photoreceptors starting to de-
generate at age 2–3 wk and complete loss of photorecep-
tors at age 8–16 wk.19 Electroretinography (ERG) studies
have demonstrated that the loss of retinal response was
dependent on the genetic background, with ERGs becom-
ing extinguished at age 6–16 wk in some strains.19 Hence,
at least one modiﬁer locus appears to slow down the rate
of degeneration in the pigmented mice compared with the
albinomice. A detailedmorphological examinationof three
rd3 strains demonstrated the degeneration of photorecep-
tors through apoptosis and has conﬁrmed the slower rate
of degeneration in pigmented rd3 mice compared with
albino strains.20
The rd3 genetic locus was mapped to mouse chromo-
some 1 betweenmarkersD1Mit292 andD1Mit510 andwas
excluded as being a mouse ortholog of one of the human
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Usher syndrome loci.21,22 Herein, we report the identiﬁca-
tion of the genes (3322402L07Rik and C1orf36—renamed
“Rd3” and “RD3,” respectively) responsible for the rd3 ret-
inopathy. We show that Rd3 is preferentially expressed in
the retina and that the rd3 mutation leads to a truncated
and relatively unstable protein in COS-1 cells. The RD3
protein is associated with promyelocytic leukemia-gene-
product (PML) bodies in the nucleus. We also describe a
large RD3-screening effort involving 881 probands with
retinopathy, revealing at least one putativedisease-causing
mutation and several changes of uncertain signiﬁcance.
Material and Methods
Histological and Electroretinogram Analysis of rd3 Mice
The studies involving mice were performed after approval from
institutional committees was obtained. Histology and electro-
retinograms were performed as described elsewhere.23
Mouse Mutation Screen
We examined genes in the published rd3 (RBF/DnJ) critical region
by direct sequencing. We additionally screened other rd3 lines
(RBJ/DnJ, STOCK Rb(11.13)4Bnr/J, and STOCK In(5)30Rk/J), as
well as wild-type (WT) mouse strains, to verify the alteration. The
following primers were used: for Rd3 exon 2, 5′-cgcctctctctttcttg-
gtg-3′ (forward) and 5′-gcgactccagtcaccttctc-3′ (reverse); for Rd3
exon 3 5′-caagagcaaggttgggagtt-3′ (forward) and 5′-tccagcattcaagg-
actcag-3′ (reverse). Exon ampliﬁcation and sequencing of another
gene, Rcor3, was initiated but was halted when the stop codon
in 3322402L07Rik was identiﬁed. PCR was performed frommouse-
tail DNA with use of standard conditions, and ampliﬁed products
were evaluated by agarose gel electrophoresis andwere sequenced
at the University of Michigan sequencing core facility.
RT-PCR and Northern-Blot Analysis
RT-PCR analysis was performed using WT mouse retinal RNA
at time points ranging from embryonic day 12 (E12) to age 4
mo and from postnatal day 2 (P2) and 4-wk-old (4W) adult
Nrl/ and Crx/mice.24,25 The primers used were Hprt 5′-caaacttt-
gctttccctggt-3′ (forward), Hprt 5′-caagggcatatccaaacaaca-3′ (re-
verse), Rd3rt 5′-gagagaggtggagcgacaac-3′ (forward), and Rd3rt 5′-
cacatcctccgagatggttc-3′ (reverse). A human multiple-tissue north-
ern blot (BD Biosciences Clontech) and a mouse retina northern
blot were probed with radiolabeled full-length Rd3 cDNA or b-
actin cDNA, as described elsewhere.26
Immunoblot Analysis
Rd3 cDNA was ampliﬁed and cloned into the pEGFPN1 vector
(BD Biosciences Clontech) with use of primers N1 5′-gacgacaagctt-
atagtggccctgaaggaggt-3′ (forward) and N1 5′-cagcagggatccgagtcgg-
cctggggcgccctgaa-3′ (reverse). Mutagenesis was performed, as de-
scribed elsewhere,27 with primersW6R 5′-atgtccctcatcccgcggctccg-
gtggaacg-3′ (forward), W6R 5′-cgttccaccggagccgcgggatgagggacat-3′
(reverse), E23D 5′-cggaccccggccgacatggtgctggagacg-3′ (forward),
E23D 5′-cgtctccagcaccatgtcggccggggtccg-3′ (reverse),K130M5′-gccc-
tggagaagatgatgcaggaggaggaggcc-3′ (forward), and K130M5′-ggcct-
cctcctcctgcatcatcttctccagggc-3′ (reverse). Primers used to transfer
Rd3 into pcDNA4c (Invitrogen) were Rd3pc 5′-gacgacggatccatgtcc-
ctcatcccgtgg-3′ (forward) and Rd3pc 5′-cagcaggcggccgccttgatgggtc-
tcctggttg-3′ (reverse). Primers (Rd3mut 5′-gctgctggctgaatgagagccc-
gaggtg-3′ [forward] and Rd3mut 5′-cacctcgggctctcattcagccagcagc-
3′ [reverse]) were used to introduce the rd3 mutation into the
mouse Rd3 cDNA. The rd3 cDNA construct was then used as a
PCR template with Rd3pcF and Rd3pcR primers. The ampliﬁed
PCR product was digested and cloned into pcDNA4. Each Rd3
mutant cDNA clone was completely sequenced. Mouse Mef2c in
pcDNA4 was used as a transfection control in some experiments.
Expression constructs were transfected into COS-1 cells with Fu-
gene 6 (Roche), according to the manufacturer’s instructions.
Cells were harvested after 48 h, with use of PBS and protease
inhibitors (Roche), and extracts were fractionated by SDS-PAGE
and were transferred to nitrocellulose membrane. The blots were
probed with rabbit anti-Green Fluroescent Protein (GFP) polyclo-
nal antibody (1:2,000) and mouse anti-beta tubulin antibody (1:
10,000) or with mouse-anti Xpress antibody (1:4,000) (Invitro-
gen) and were visualized using appropriate secondary antibodies
and luminescence (Pierce).
Localization in COS-1 Cells
Cells were washed with PBS 48 h after transfection, were ﬁxed
using 4% paraformaldehyde/PBS for 15 min, and were washed
again in PBS. Cells were permeabilized using 0.05% TritonX-100/
PBS (PBS-T) for 10 min. After washing, a 5% BSA/PBS solution
was applied, and the cells were blocked for 30 min. The primary
antibodies used were anti-coilin antibody ab11822 (1:50) (Ab-
cam), anti-SC-35 antibody ab11826 (1:50) (Abcam), anti-PML
antibody sc-5621 (1:50) (Santa Cruz Biotechnology), and anti-
Xpress antibody (1:400) (Invitrogen). The cells were incubated
for 1 h in 1% BSA/PBS with primary antibody, were washed with
1% BSA/PBS, and were incubated with the appropriate secondary:
anti-rabbit IgG Alexa ﬂuor 546, anti-mouse IgG Alexa ﬂuor 546,
or anti-mouse IgG Alexa ﬂuor 488 (Molecular Probes) (1:750 di-
lution). Cells were washed with 1% BSA/PBS, were counterstained
with bisbenzimide to stain nuclei, and were examined by ﬂuo-
rescent microscopy.
Human-Mutation Screen
All human studies were performed in a manner consistent with
the Declaration of Helsinki and were approved by the respective
institutional review boards. Appropriate informed consent was
obtained from study subjects. We performed a three-continent
(North America, Asia [India], and Europe [United Kingdom and
Scandinavia]) human-mutation screen of the RD3 gene. Clinical
phenotypes observed among the North American patient pool
included simplex RP, multiplex RP, juvenile (early-onset) RP, re-
cessive RP, cone-rod dystrophy (CRD), Leber congenital amauro-
sis (LCA [MIM #204000]), partial cone degeneration, fundus al-
bipunctatus, atypical pattern dystrophy, macular degeneration,
Stargardt disease, autoimmune retinopathy, achromatopsia, con-
genital stationary night blindness, and enhanced S-cone syn-
drome. For the North American and European screen, the follow-
ing primers were used: for exon 2, RD3 5′-ctgttagggcagagcaggtc
(forward) and RD3 5′-ctctagtcctggtggcctca (reverse); for exon 3,
RD3 5′-ggactaattggccatgagga (forward) and RD3 5′-ctttgtggccagag-
gaagag (reverse). The screen in India used exon 2 5′-ttcccaggttcc-
ccactctg-3′ (forward) and 5′-ccactgcagccacctttcct-3′ (reverse) and
exon 3 5′-gacgcccggggtgccagac-3′ (forward) and 5′-gttccagggcccgg-
cgct-3′ (reverse). PCR was performed using standard conditions,
and products were subjected to direct sequencing. Sequencing
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Figure 1. Pedigree of the rd3 mouse strains. Four male mice were collected in Switzerland in 1969 and were genetically ﬁxed to
several lines. The mouse strains are currently housed at the Jackson Laboratory. This pedigree was updated from an earlier version,19
with the kind permission of Springer Science and Business Media.
was performed at the University of Michigan sequencing core, at
Bangalore Genei (Bangalore, India), and at the Institute of Oph-
thalmology (London). We performed RFLP analysis to determine
segregation of a splice-site change within the LCA-affected family
and to examine 121 unrelated ethnically matched unaffected
controls. This change leads to the abolition of a restriction site
for Hph1. The normal allele in a 436-bp ampliﬁed PCR product
is digested into 387 bp and 49 bp fragments, whereas the ho-
mozygous mutated allele shows a 436-bp product.
Results
rd3 Mouse Strains and Visual-Function Analysis
The rd3 mutation has been bred into different strains of
mice and now exists in ﬁve separate strains—RBF/DnJ,
STOCK In(1)Rk/J, STOCK In(5)30Rk/J, RBJ/DnJ, and STOCK
Rb(11.13)4Bnr/J (hereafter termed “4Bnr”). An updated
pedigree of rd3-bearing mice is shown in ﬁgure 1.19 His-
tologically, STOCK In(5)30Rk/J mice have a modest re-
duction in outer nuclear layer (ONL) thickness, with 3–5
rows of nuclei left at age 35 d. In contrast, the RBF/DnJ
albino strain has a fully degenerated retina at the same
age. The 4Bnr albino strain had the least degenerate retina
of the three assessed rd3/rd3 mice, but some degeneration
was observed at the earlier time point of 27 d (ﬁg. 2A).
For comprehensive evaluation of rod and/or cone pho-
toreceptor dysfunction, we performed dark-adapted (rod
photoreceptor derived) and light-adapted (cone pho-
toreceptor derived) ERG tests on STOCK In(5)30Rk/J,
4Bnr, and RBF/DnJ rd3/rd3 strains, with C57BL/6J mice as
controls. In a previous study, rod derived ERG showed
progressive retinal functional loss in rd3 mice; no cone
ERG was reported.19,28 We found that the amplitude of
the loss of dark-adapted ERG varied, depending on the
mouse strain. The In(5)30Rk/J (pigmented) strain had dark-
adapted ERG closer to the WT at both age 24 d and age
32 d. The 4Bnr (albino) strain had a large response at day
17, but ERG was reduced at day 24. Lastly, the ERG in the
RBF/DnJ (albino) strain was almost undetectable at age
24 d and was completely abolished by age 31 d (ﬁg. 2B,
top panel). All three strains of rd3/rd3 mice had greatly
reduced or nondetectable light-adapted ERGs by age 24
d (ﬁg. 2B, bottom panel, and data not shown). These re-
sults demonstrate that both rod and cone photoreceptors
in the rd3 homozygotes are functionally affected.
Mutation Screen of rd3 Mice
To identify the rd3 mutation, we screened candidate genes
in the mapped rd3 region (ﬁg. 3A) that had been deﬁned
elsewhere.21 The critical genomic region was ∼1 Mb and
contained 13 genes or expressed sequences (National Cen-
ter for Biotechnology Information [NCBI]MapViewerbuild
36.1). To select candidates for mutation analysis, we ﬁrst
examined the expression proﬁle of all genes in silico and
through our microarray proﬁling, as reported elsewhere.29
The Riken cDNA 3322402L07 showed a twofold increase
in expression from P2 to P10 in puriﬁed rod photorecep-
tors29 (A. Swaroop, M. Akimoto, and H. Cheng, unpub-
lished data). Hence, we selected it as a candidate gene for
the rd3mutation screen. Complete sequencing of all exons
and intron-exon boundaries (ﬁg. 3B) revealed a homo-
zygous c.319CrT transition in the third exon. This change
alters codon 107 from CGA to TGA, thus converting ar-
ginine to a stop codon, and is predicted to result in pre-
mature truncation of the RD3 protein. The mutation was
detected in all rd3 lines tested (RBF/DnJ, RBJ/DnJ, 4Bnr,
and STOCK In(5)30Rk/J) but not in the nine control WT
mouse lines (C57BL/6J, A/J, AE/J, BALB/cJ, C3H/HeJ, CBA/
J, DBA/2J, MOLC/RkJ, and NON/LtJ) (ﬁg. 3C). To further
conﬁrm whether this is indeed the causative mutation in
rd3-containing strains, we generated haplotypes using
markers spanning the rd3 locus.21 The three markers—
1062 The American Journal of Human Genetics Volume 79 December 2006 www.ajhg.org
Figure 2. A, Histology of rd3/rd3 mice. We examined STOCK In(5)30Rk/J, 4Bnr, RBF/DnJ (all rd3/rd3), and control C57BL/6J mice at
ages 35, 27, 35, and 28 d, respectively. B, top, ERG responses under dark-adapted conditions: STOCK In(5)30Rk/J(rd3/rd3) mice (aged
32 d), 4Bnr(rd3/rd3) mice (aged 24 d), RBF/DnJ(rd3/rd3) mice (aged 31 d), C57BL/6J mice (aged 31 d). Bottom, Light-adapted ERG
responses of the same mice.
D1Mit292.1, D1Mit462.2, and D1Mit511—revealed iden-
tical alleles in the three tested rd3 lines (data not shown),
which is consistent with the presence of the rd3 mutation
in this genetic background.
Analysis of the Rd3 Gene
To determine the expression proﬁle of the Rd3 transcript,
we performed northern-blot and RT-PCR analysis using
RNA from human and mouse tissues. The Rd3 transcript
of 1.9 kb was enriched in adult-mouse retinal tissues and
had no detectable expression in nonretinal adult-human
tissues, as revealed by human multiple-tissue northern-
blot analysis (data not shown). We then examined its ex-
pression using WT, Nrl/, and Nrl/ mouse retinal RNA
by northern-blot analysis. WT mice and Nrl/ mice have
a rod/photoreceptor–dominated retina,whereasNrl/mice
lack rods and instead have a cone-dominant retina.24 Rd3
is transcribed as a single RNA in these strains, with no
obvious difference (data not shown).
To elucidate developmental expression of Rd3, we per-
formed RT-PCR experiments using mouse retinal RNA from
E12 to age 4 mo (ﬁg. 4A). The Rd3 transcript is detected
at very low levels at E12 but was more noticeable begin-
ning at E18, with subsequent increase in expression at P2
and P6. After P6, the levels of Rd3 transcript remained
high. Additional RT-PCR experiments were performed us-
ing retinal RNA fromNrl/ (aged P2 and 4W), Crx/ (aged
P2 and 4W), rd1 (adult), and rd16 (adult) mice. The Nrl/
mouse lacks rod photoreceptors, whereas theCrx/mouse
exhibits a lessening of rod and cone gene expression at
P10 and exhibits photoreceptor degeneration at age 2
mo.24,25 The rd1 and rd16 homozygotes exhibit early-onset
degeneration of photoreceptors.9,13 The detection of the
Rd3 transcript in all mutant mouse strains suggests that
it is also expressed in inner retina cell types (ﬁg. 4B). Our
data are consistent with the expression proﬁle for C1orf36
(Hs.632495 [NCBI Expression Proﬁle Viewer]) and previous
in situ hybridization experiments,30,31 which demonstrate
high expression of 3322402L07Rik cDNA in the ONL in
addition to the other cellular layers of the retina.
Clustal analysis of the RD3 protein orthologs suggests
its strong conservation in vertebrates, from human to ze-
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Figure 3. A, Critical genomic region encompassing the rd3 mutation, between markers D1Mit292 and D1Mit510.21 Genes within the
critical region are indicated. B, Genomic structure of the mouse Rd3 gene. C, Chromatogram showing the region of the Rd3 (3322402L07Rik)
molecular defect in rd3/rd3 strains RBF/DnJ, RBJ/DnJ, STOCK Rb(11.13)4Bnr/J, STOCK In(5)30Rk/J, and WT control strains C57BL/6J,
A/J, AE/J, BALB/cJ, C3H/HeJ, CBA/J, DBA/2J, MOLC/RkJ, and NON/LtJ. The homozygous CrT change in the rd3-bearing mice is
indicated. It generates a stop codon after aa 106.
braﬁsh (ﬁg. 4C). An in silico analysis of the mouse and
human RD3 proteins reveals a coiled-coil domain at aa
22–54 and another weaker coiled-coil domain at aa 121–
141.32 The RD3 protein also has several putative protein
kinase C and consensus Casein kinase II phosphorylation
sites and one predicted sumoylation site. The mouse and
human RD3 orthologs are basic proteins, with isoelectric
points of 8.9 and 7.7, respectively.
Immunoblot analysis of COS-1 cells transfected with an
Rd3-expression construct in the EGFPN1 vector demon-
strated an expected RD3-GFP–fusion protein of ∼45 kDa
(predicted molecular mass of RD3 is ∼22 kDa and that of
GFP is ∼23 kDa) (ﬁg. 4D).
Localization of the RD3 Protein in Transfected COS-1 Cells
In transfected COS-1 cells, the RD3-GFP–fusion protein
primarily exhibited nuclear or nuclear/cytoplasmic local-
ization (ﬁg. 5A–5D and data not shown). Some cells also
contained a putative aggresome-like staining adjacent to
the nucleus—likely because of the overexpression of the
RD3 protein (data not shown). The most striking pattern
was the presence of subnuclear spots, henceforth named
“RD3 bodies,” of different sizes (ﬁg. 5A–5C). We examined
whether RD3 bodies colocalized with other subnuclear
proteins, such as coilin (Cajal body marker), SC-35 (Nu-
clear Speckle marker), and promyelocytic leukemia gene
product (PML body marker). Coilin staining did not lo-
calize near RD3 bodies in a consistent manner, suggest-
ing that they are not associated (ﬁg. 5A). SC-35 staining
tended to be diffuse and localized near RD3 bodies (ﬁg.
5B). PML staining also existed near RD3 bodies, with an
occasional overlap (ﬁg. 5C and 5G). To further conﬁrm
close PML proximity, we performed the same experiment
using an Xpress-tagged Rd3 plasmid. The Xpress-RD3 pro-
tein demonstrated a more highly varied localization pat-
tern than did RD3-GFP, suggesting that the size of the tag
may impact the distribution of transfected RD3 protein
(ﬁg. 5E and 5F). Nonetheless, we observedmany cells with
similar RD3 bodies in close proximity to PML bodies in
Xpress-Rd3–transfected cells (ﬁg. 5E and 5H).
Analysis of the rd3 Mutation
To determine the consequence of the rd3 mutation, we
introduced this sequence alteration into the Rd3-pcDNA4
construct. Immunoblot analysis of COS-1–transfected cells
revealed a truncated mutant RD3 protein (∼11 kDa  ∼4
kDa Xpress epitope), which was consistently detected at
reduced levels compared with the WT protein (∼22 kDa
∼4 kDa Xpress epitope) (ﬁg. 6A). The mutant truncated
protein therefore appears to be unstable and prematurely
degraded. The mouse Mef2c-pcDNA4 construct was used
as an internal control for transfection and was detected
in roughly equal amounts in all experiments (ﬁg. 6A). By
immunocytochemistry, Xpress-RD3 mutant protein could
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Figure 4. Expression of the Rd3 gene. A, Rd3 transcripts in mouse retina (aged E12 to 4 mo), present from at least E18, with a large
increase from age P2 to age P6. Hprt was used to evaluate RNA quality and to normalize for quantity. B, Expression of Rd3 in Nrl/,
Crx/, rd1/rd1, and rd16/rd16 mouse retina cDNA from P2, 4W, or adult. Hprt was used as a positive control. C, Alignment of RD3
protein orthologs. The amino acid sequence of mouse RD3 protein is aligned with those of human, chimpanzee, macaque, cow, opossum,
frog, chicken, tetraodon, fugu, and zebraﬁsh. Amino acid residues conserved in all orthologs are indicated by an asterisk (*), and
reduced identity is shown using either a colon (:) or a dot (•). The long bar denotes a highly conserved coiled-coiled domain. D,
Immunoblot expression of RD3-GFP fusion protein. An expression construct containing Rd3-GFP cDNA was transfected into COS-1 cells
and was examined by immunoblot with use of anti-GFP antibody. The observed band is approximately the size estimated for the fusion
protein (∼50 kDa). A lower band of 30 kDa may represent a putative degradation product. Beta-tubulin was used to normalize for
loading. UNTR p untransfected.
be observed in COS-1 cells, but at much lower levels com-
pared with the WT protein at similar exposure times (ﬁg.
6B–6D).
Human RD3-Mutation Screen
To examine whether mutations in the human RD3 gene
are associated with retinal disease, we performedmutation
screening of 461 probands with retinopathy from North
America (including at least 30 with cone dystrophy or
CRD and 15 probands with LCA), 103 probands of Indian
descent who had retinal dystrophy, 302 probands (177
with autosomal dominant RP, 96 with autosomal recessive
RP, and 29 with cone dystrophy or CRD) from the United
Kingdom, and 15 probands with CRD from Scandinavia.
We sequenced all coding exons, including the ﬂanking
intron/exon boundaries (ﬁg. 7A).
Of particular interest were two siblings from India who
had LCA (ﬁg. 7B). Both probands have had poor vision
since birth: nystagmus and atrophic lesions in themacular
area, with pigment migration. Fundus photographs of the
affected siblings are shown in ﬁgure 7C. A homozygous
GrA transition in the donor splice site at the end of exon
2 (c.2961GrA) was observed in both siblings (ﬁg. 7D).
When the splice site is removed, the 99th codon still en-
codes arginine and is followed by a stop codon, suggesting
that the protein is prematurely truncated. RFLP analysis
of other family members demonstrated that the homo-
zygous change was present only in the affected members
of the family, with unaffected members heterozygous for
the mutation (ﬁg. 7E). We examined 121 unrelated eth-
nically matched controls by RFLP and did not observe this
nucleotide substitution. The GrA alteration was not ob-
Figure 5. Immunolocalization of the RD3 protein. Mouse Rd3 cDNA was placed in either the pEGFPN1 or the pcDNA4 vector and was
expressed in COS-1 cells. The cells were observed directly via GFP or with use of an anti-Xpress antibody (green). Cells were also stained
with subnuclear markers (red), to test for colocalization. Bisbenzimide was used to stain the nuclei (blue). A, RD3-GFP and Cajal body
marker anti-coilin. B, RD3-GFP and nuclear speckle marker anti-SC-35. C and D, RD3-GFP and PML body marker anti-PML. E and F, Xpress-
RD3 and anti-PML antibody. G and H, Higher magniﬁcation of the merged images from panels C and E, respectively. Close localization
of RD3 and PML bodies are marked with an arrowhead and an arrow, respectively.
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Figure 6. A, Examination of the mouse rd3 mutation in COS-1
cells. Equal amounts of WT (lane 1) and mutant (lane 2) Rd3-
pcDNA4 vectors were cotransfected with Mef2c-pcDNA4 into COS-
1 cells. Cells were examined by immunoblot with use of anti-Xpress
antibody. Roughly equal intensity of MEF2C signal shows that equal
amounts of protein were loaded on the gel. WT RD3 protein is of
expected molecular mass (∼26 kDa), whereas the mutant RD3 pro-
tein is truncated (∼15 kDa) and is expressed at lower levels. B,
Immunolocalization of the RD3 protein in transfected cells, with
use of WT rd3-pcDNA4 construct. Bisbenzimide was used to stain
the nuclei (blue). C and D, Immunolocalization of the RD3 protein
in transfected cells, with use of mutant rd3-pcDNA4 plasmid. Cells
were examined as in panel B. Image exposures were performed in
a consistent manner.
served in any other probands or controls from North
America or Europe. To directly examine the impact of this
change on RD3 transcript, we performed RT-PCR analysis
of RNA from control lymphocytes, but no product could
be ampliﬁed (data not shown).
Our mutation screening uncovered changes of uncertain
signiﬁcance in three female probands. The ﬁrst affected in-
dividual (from North America) revealed four homozygous
alterations (c.16TrC, 69GrC, 84GrA, and 235TrC) lead-
ing to two predicted amino acid changes (p.W6R, E23D,
T28T, and L79L, respectively). She exhibited an atypical
late-onset form of RP. The second proband (also from
North America) carried a heterozygous c.389ArT altera-
tion encoding a predicted p.K130M. This girl presented in
1996, then aged 11 years, with a history of poor vision
beginning at age 3 years but with no family history of
eye problems or blindness. Fundus examination showed
round atrophic lesions in both maculae, and there was a
cellophane-like sheen and atrophy in the other regions of
the posterior poles. By ERG, it was determined that she
had a CRD pattern, with cone ERG b-wave amplitudes at
about one-third of normal and rod ERG amplitudes at
∼80% of normal levels. The third proband (from Scandi-
navia) had a heterozygous c.170GrT change encoding
p.G57V. She had no family history of visual handicap but
had visual problems since age 6 years. Her eye disorder
was diagnosed by repeated full-ﬁeld ERG, at ages 9 years
and 19 years, as cone-rod degeneration with reduced but
still-remaining rod and cone function. At age 19 years,
fundus examination revealed macular changes with at-
rophy and spicular pigment in the midperiphery. Visual
acuity was reduced to 20/200, with central scotoma in
both eyes.
Several other alterations were observed in the hetero-
zygous form, both in probands and in controls, or did not
segregate with the disease in affected families; these in-
clude c.103GrA (p.G35R), c.139CrT (p.R47C), c.202CrT
(p.R68W), c.500GrA (p.R167K), and c.584ArT (p.D195V).
The population group and frequency of each alteration
are listed in table 1.
To examine whether missense alterations observed in
the human mutation screen affected subcellular localiza-
tion of the RD3 protein, we generated p.W6R, p.E23D,
p.K130M, and p.W6R;E23D mutations in the RD3-GFP–
expression construct. These changes were selected because
of their absence in normal controls and their presence in
individual probands. The GFP-fused mutant RD3 proteins
did not appear to have a substantive difference from the
control in immunoblot analysis or in COS-1 localization
(data not shown). Overall, our data suggest that RD3 mu-
tations represent a rare cause of retinopathy.
Discussion
RDs are a signiﬁcant cause of untreatable blindness in the
United States. Delineation of precise genetic defects in RDs
and of cellular pathways that lead to photoreceptor-cell
death are critical for developing knowledge-based design
of treatment and therapies. In our continuing effort to
identify retinal-disease genes, we have uncovered genetic
defects in the RD3 gene that are responsible for photo-
receptor degeneration in the rd3mouse and some patients
with retinopathies. Notably, RDs can be caused by mu-
tations in photoreceptor-speciﬁc (such as rhodopsin, RP1,
CRX, and NRL) or ubiquitously expressed (such as RPGR,
CHM, and PRPF31) genes. The RD3 gene exhibits an in-
teresting expression proﬁle: whereas it is preferentially
(and highly) expressed in the retina and in photorecep-
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Figure 7. Findings for the LCA-affected family (from India), with a homozygous change in RD3. A, Genomic structure of the human
RD3 gene. B, Pedigree of family 146. Proband 146/4 is marked with an arrow. C, Fundus photographs of affected individuals 146/4 and
146/6. D, Chromatograms of unrelated unaffected subject and affected proband 146/6 at the exon2/intron2 junction. Individual 146/
6 has a homozygous GrA change, which is predicted to remove the donor splice site of exon 2 and result in a stop codon after aa
99. E, Pedigree of a portion of family 146 and RFLP analysis of the mutation. Probands 146/4 and 146/6 show only a 436-bp band,
whereas all other members show 49-bp and 387-bp bands in addition to the 436-bp band. UD p undigested.
tors, Rd3 transcripts can be detected in mouse retinas that
lack rod and cone photoreceptors.
The RD3 protein has a relatively low molecular mass
(22 kDa) and includes a number of conserved sites for
protein modiﬁcation (speciﬁcally, phosphorylation and
sumoylation). Additionally, the putative coiled-coil do-
main(s) might serve as protein-interaction site(s). Themu-
tation identiﬁed in the rd3 mouse generates a stop codon
in the Rd3 gene, thereby producing a truncated protein
(of 11 kDa) that appears to be less stable, at least in trans-
fected COS-1 cells. Hence, our data strongly implicate par-
tial or complete loss of RD3 protein function as a possible
mechanism of retinal degeneration in the rd3 mouse. Al-
though the rd3 mutation is in the last exon, nonsense-
mediated decay of the mutant transcript cannot be ruled
out. In any event, the detection of a truncated RD3mutant
protein in COS-1 cells further validates the causal rela-
tionship of this mutation to retinopathy.
Subnuclear structures that commonly exist in cells in-
clude PML bodies, Cajal bodies, and nuclear speckles. PML
bodies are implicated in diverse biological functions, in-
cluding DNA repair, antiviral response, apoptosis, proteo-
lysis, gene regulation, and tumor suppression.33–35 PML is
also suggested to be a transcriptional regulator and/or sen-
sor of DNA damage and cellular stress.33–35 Cajal bodies are
associated with snRNPs and snoRNPs (small nuclear and
nucleolar RNAs), which are involved in pre-mRNA and
rRNA processing, respectively.36 Nuclear speckles are ob-
served close to genes with highly active transcription, are
linked with pre-mRNA splicing, and are suggested to form
a compartment for splicing factors and proteins involved
in transcription.37 Interestingly, a number of retinopathy
genes are associated with transcription and splicing.16,38–45
Varied localization of RD3 protein in COS-1 cells suggests
its dynamic role in cellular processes and within subnu-
clear compartment(s). A reduced amount of mutant RD3
protein in transfected cells indicates that the loss of RD3
protein may compromise nuclear function(s). However,
the precise role of RD3 in transcription, splicing, or other
regulatory processes is subject to further experimentation.
LCA is a cause of early-onset (childhood) blindness,with
an estimated prevalence of 1 in 50,000–100,000.46 Known
and putative functions and/or location of proteins en-
coded by mutant LCA genes are diverse and include pro-
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Table 1. Summary of the RD3 Human Mutation Screen
Change
No. of Subjects with Exon Change
United Kingdom/
Scandinavia India North America
Proband
(np 317)
Control
(np 95)
Proband
(np 103)
Controla
(np 121)
Proband
(np 461)
Control
(np 175)
Homozygous c.16TrC, 69GrC, 84GrA, 235TrC
(p.W6R, E23D, T28T, L79L) 0 0 0 NA 1 0
c.103GrA (p.G35R) 0 0 1 NA 0 0
c.139CrT (p.R47C) 8 2 2 NA 10 5
c.170GrT (p.G57V) 1 0 0 NA 0 0
c.202CrT (p.R68W) 0 0 1 NA 0 0
c.389ArT (p.K130M) 0 0 0 NA 1 0
c.500GrA (p.R167K) 3 0 0 NA 1 1
c.584ArT (p.D195V) 1 3 0 NA 4 6
c.2961GrA homozygous 0 0 1b 0 0 0
NOTE.—Probands with RP were sequenced for changes in exon 2 and exon 3 of RD3.
a The c.2961GrA mutation was examined in 121 Indian controls by RFLP. NA p not applicable.
b One proband was found in the initial screen. An affected sibling was subsequently identiﬁed during follow-up.
tein trafﬁcking, cell-cycle progression, photoreceptormor-
phogenesis, transcription, phototransduction, and retinoid
cycle.4,13,18,47 RD3 is likely responsible for a small subset of
LCA, and further examination of this retinopathy might
allow us to determine the proportion of RD3 mutation–
based early-onset retinopathy. We have identiﬁed two sib-
lings carrying a mutation in the invariant G residue of the
exon 2 donor splice site. Splice-site alterations are respon-
sible for at least 15% of human mutations.48 Mutation of
the invariant G at donor splice site 1 is a commonly
reported cause of human disease (Human Gene Mutation
Database).49 It is possible that a cryptic splice site within
exon 2 or intron 2 is used after the invariant G is changed.
Additionally, exon 2 may be skipped entirely,50 or the
mRNA may be subject to nonsense-mediated decay.51With-
in exon 2, there are two potential cryptic splice sites—
c.159 and c.169—with scores of 0.50 and 0.43, respec-
tively. After the normal exon 2 splice site, the next pu-
tative splice sites are at nucleotides c.296219 and c.296
432 (respective scores 0.41 and 1.00). The likely splicing
site for mutant allele is c.296432, because of its high
score52 (Berkeley Drosophila Genome Project: Splice Site
Prediction by Neural Network Web site). The splice-site
mutation is predicted to result in a truncated RD3 protein,
ending at aa 99. This shortened protein would be similar
to the 107-aa protein in the rd3 mice, thereby raising the
possibility that the rd3 mouse is a useful mouse model for
the retinal disease in this family. Notably, the rd3 mice
exhibit a relatively quick degeneration of photoreceptors.
For example, ONL loss in RBF/DnJ-rd3/rd3 mice is com-
plete in ∼8 wk.19 In comparison, the quite severe Pde6brd1
and Rd4 mouse retinas show severe degeneration by age
1 mo and 2 mo, respectively.53 Several strains of mutant
mice reveal much slower photoreceptor loss than do rd3,
with complete degeneration as late as age 30 mo.53
In the one proband carrying four homozygous altera-
tions, W6 and E23 residues are conserved in almost all spe-
cies. Codon 6 in chimpanzee is arginine (instead of tryp-
tophan), and codon 23 in frog is aspartic acid (instead of
glutamic acid). Since W6R and E23D alterations exist in-
dividually in chimpanzee and frog, it is difﬁcult to con-
clude whether these changes cause disease in humans.
Additional work would be required to fully characterize
the functional effect of these alterations. For c.389ArT
(p.K130M)– and c.16TrC;69GrC;84GrA;235TrC(p.W6R;
E23D;T28T;L79L)–containing probands, we attempted
to collect DNA samples from the respective families but
were unsuccessful. Although c.389ArT (p.K130M) and
c.170GrT (p.G57V) heterozygous changes are not ob-
served in our cohort of controls, we learned that these
subjects are of Chinese and mixed European–Middle East-
ern decent, respectively. Screening of ethnically matched
controls might be necessary to determine whether these
changes are polymorphic in their respective populations.
We identiﬁed several additional nucleotide changes that
do not appear to be associated with disease in hetero-
zygous state; these are c.103GrA (p.G35R), c.139CrT
(p.R47C), c.202CrT (p.R68W), c.500GrA (p.R167K). and
c.584ArT (p.D195V).
Since the splice–site alteration represents the only likely
disease-causing mutation in 881 examined probands, we
suggest that RD3 mutations are a rare cause of retinal
disease. C1orf36 (RD3) was tested elsewhere as a candi-
date retinal-disease gene; however, no signiﬁcant altera-
tions were observed in this earlier study.30 Recently, initial
screening of coding regions in patients with retinopathy
did not reveal any disease-causing mutation in CEP290/
NPHP6, and only the lymphocyte RNA analysis estab-
lished it as a major LCA gene.18 However, unlike CEP290,
RD3 is not detected in lymphocytes.
Recent studies suggest a more dynamic environment in
the nucleus than previously expected.54 Discrete nuclear
processes (such as steps in gene transcription and post-
transcriptional events) appear to be mediated by associa-
tion of gene regions, transcribed sequences, and/or pro-
teins in unique subnuclear compartments. PML bodies are
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but one component of the nucleus whose role(s) is not
completely understood. The discovery of RD3 and its fur-
ther characterization might allow us to gain insights into
fundamental regulatory events that are necessary for ret-
inal function.
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